Baird lowered the firm’s price target on Dianthus (DNTH) to $50 from $58 and keeps an Outperform rating on the shares. The firm updated its model following Q1 results where the company updated it product pipeline.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DNTH:
- Promising Developments and Strong Financials Support Buy Rating for Dianthus Therapeutics
- Dianthus Therapeutics Reports Increased R&D Expenses
- Promising Outlook for Dianthus Therapeutics: Buy Rating Backed by Clinical Progress and Financial Stability
- Dianthus completes enrollment for Phase 2 MaGic Trial of DNTH103
- Short Report: Bears bite into solar with higher exposure to Sunrun, SolarEdge